Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
Authors' conclusion
In this real-world cohort, oral semaglutide provided sustained improvements in glycaemic control, body weight, and lipid profile, with preserved renal function and high treatment persistence over 24 months.
Study context
- Population
- Adults with T2D initiating oral semaglutide at an Italian diabetes clinic
- Participants
- 232 adults
- Outcome
- Change in HbA1c and body weight
- Follow-up
- 24 months
Methodological detailsreal-world, single-centre
- Real-world
- Single-centre
Main finding
As reported in the abstract
24 months
HbA1c change
−0.8%
p < 0.0001
Body weight change
−5.7 kg
p < 0.0001
Observational data: associations, not effects.
Further findings
Composite endpoint: HbA1c ≤ 7% and ≥ 5% weight loss · 24 months
- Composite endpoint progressively achieved
- 44.0%
HbA1c by non-breakfast administration
- Non-breakfast administration independently associated with lower HbA1c, adjusted for BMI, age and sex (β, p = 0.041)
- −0.32
eGFR, urinary albumin-to-creatinine ratio (UACR) and lipid profile · 24 months
- eGFR and UACR remained stable
- Total and LDL cholesterol decreased significantly (both p < 0.0001)
Treatment persistence · 24 months
- Treatment persistence at 24 months
- 68.5%
- Mean persistence
- 19.4 months
Switch to another GLP-1 RA among discontinuers
- Switching to another GLP-1 RA, most common strategy among discontinuers
- 36.2%
- Further HbA1c reduction after switching (Δ, p = 0.005)
- −0.98%
Safety
- No safety concerns emerged
Original publication
Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes. Diabetes Obes Metab. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →